MEDIUM confidence: 100% data completeness, but the composite (53) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Fewer than 3 analysts refreshed a price target in the last month, so no revision can be computed. Prior quarter: $31 avg across 4 analysts.
Buy-rated share 38% → 34% over ~3 months (-3pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $0.68 | $0.77 | +12.9% |
| May 2026 | $0.72 | $0.75 | +3.9% |
| Feb 2026 | $0.57 | $0.66 | +16.4% |
| Nov 2025 | $0.63 | $0.87 | +37.4% |
| Aug 2025 | $0.58 | $0.78 | +34.5% |
| Apr 2025 | $0.67 | $0.92 | +38.1% |
| Feb 2025 | $0.47 | $0.63 | +33.6% |
| Oct 2024 | $0.61 | $1.06 | +72.6% |
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $81.3B— | $101.2B+24.5% | $59.6B-41.1% | $63.6B+6.8% | $62.6B-1.6% |
| EPS (dil.) | $3.88— | $5.47+41.0% | $0.37-93.2% | $1.41+279.8% | $1.36-3.5% |
| Free Cash Flow | $29.9B— | $26.0B-12.8% | $4.8B-81.6% | $9.8B+105.2% | $9.1B-7.7% |
| Gross Margin | 62.1% | 66.1%+4.0pp | 58.1%-8.0pp | 71.9%+13.8pp | 74.3%+2.4pp |
| Operating Margin | 24.9% | 37.7%+12.8pp | 7.4%-30.3pp | 23.5%+16.1pp | 27.8%+4.3pp |
| Net Margin | 27.0% | 31.0%+4.0pp | 3.6%-27.4pp | 12.6%+9.1pp | 12.4%-0.2pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net insider $2.8M over 180 days (3 open-market buys, 2 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of -3.8%/yr (revenue basis).
Base free cash flow $7.9B (avg FY2023–FY2025; latest year $9.1B) · equity value $174.1B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Pfizer's QScore of 53 indicates a neutral outlook, driven by strong momentum and reasonable profitability, but offset by lackluster growth and a premium valuation, with a P/E of 40.4. The stock exhibits strong momentum, with a 25.6% return over the past year and a bullish 50-day versus 200-day moving average trend. While the long-term and short-term scores are relatively aligned, the company's growth metrics, such as -1.6% revenue growth and -4.2% EPS growth, weigh on its overall score.